What does this research mean for the field?

SGLT2 inhibitors reduce the risk of atrial fibrillation through multifaceted hemodynamic, metabolic, and electrophysiological mechanisms, particularly benefiting patients with type 2 diabetes and heart failure. Novelty: ClaimNovelty.SYNTHESIS. Consensus alignment: ConsensusAlignment.SUPPORTS_CONSENSUS.

November 6, 2023Open Access

The Complex Interplay Between SGLT2 Inhibitors and Atrial Fibrillation: Mechanisms and Clinical Implications

View Full Paper

Ask AI

Bookmark

Why the study?

Do SGLT2 inhibitors reduce the risk of atrial fibrillation in patients with type 2 diabetes and heart failure?

Structured PICO

Do SGLT2 inhibitors reduce the risk of atrial fibrillation in patients with type 2 diabetes and heart failure?

Population

Patients with type 2 diabetes and heart failure

Intervention

SGLT2 inhibitors (particularly dapagliflozin and empagliflozin)

Outcome

Risk of atrial fibrillation

SGLT2 inhibitors offer a holistic approach to reducing the risk of atrial fibrillation, especially in high-risk populations with type 2 diabetes and heart failure.

Implication

May support AF risk reduction with SGLT2 inhibitors in T2D/HF; leaves open causal confirmation in RCTs.

Abstract

This comprehensive review delves into the intricate relationship between Sodium-GlucoseCo-Transporter 2 (SGLT2) inhibitors and AF, highlighting the multifaceted actions of thesedrugs and their significant cardiovascular benefits. Mechanisms: SGLT2 inhibitors inducesubstantial hemodynamic changes, impacting blood pressure, adipose tissue function, andinflammation. They enhance glycemic control while potentially reducing oxidative stress andinflammation, and they modulate atrial electrophysiology, collectively contributing to the reductionof AF risk. Clinical Evidence: This review synthesizes a wealth of clinical evidence,drawing from observational studies and randomized controlled trials, consistently demonstratinga correlation between SGLT2 inhibitors, particularly dapagliflozin and empagliflozin, anda decreased risk of AF. This protective effect is most pronounced in patients with type 2 diabetesand heart failure, underscoring their potential as therapeutic agents for high-risk populations.Potential Benefits: SGLT2 inhibitors offer a spectrum of potential benefits, includingsubstantial reductions in AF risk, particularly in patients with type 2 diabetes and heart failure.These drugs have consistently demonstrated benefits in reducing heart failure hospitalizations,cardiovascular mortality, and stroke risk, which indirectly contribute to better AF management.Furthermore, SGLT2 inhibitors exhibit renoprotective properties by slowing theprogression of chronic kidney disease and reducing albuminuria, offering substantial benefitsfor AF patients with comorbid kidney disease. Metabolic improvements involving weight loss,blood pressure reduction, and favorable changes in lipid profiles contribute to enhanced cardiovascular health and reduced AF risk. Originally designed for diabetes management, thesemedications offer a holistic approach to AF risk reduction, particularly in patients with type 2diabetes and heart failure.